{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:33:36Z","timestamp":1768084416009,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/aps.2017.100","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T10:01:57Z","timestamp":1505383317000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro"],"prefix":"10.1038","volume":"39","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-shun","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-ping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-he","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-bin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"BFaps2017100_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/cgt.2011.7","volume":"18","author":"RM Eager","year":"2011","unstructured":"Eager RM, Nemunaitis J . Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18: 305\u201317.","journal-title":"Cancer Gene Ther"},{"key":"BFaps2017100_CR2","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1158\/1078-0432.CCR-06-1491","volume":"12","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006; 12: 6523\u201331.","journal-title":"Clin Cancer Res"},{"key":"BFaps2017100_CR3","doi-asserted-by":"publisher","first-page":"e21307","DOI":"10.1371\/journal.pone.0021307","volume":"6","author":"H Jin","year":"2011","unstructured":"Jin H, Lu S, Yang J, Wang X, Hu H, Su C, et al. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One 2011; 6: e21307.","journal-title":"PLoS One"},{"key":"BFaps2017100_CR4","first-page":"1562","volume":"20","author":"PA Vasey","year":"2002","unstructured":"Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent\/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562\u20139.","journal-title":"J Clin Oncol"},{"key":"BFaps2017100_CR5","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-10-0791","volume":"16","author":"KJ Kimball","year":"2010","unstructured":"Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010; 16: 5277\u201387.","journal-title":"Clin Cancer Res"},{"key":"BFaps2017100_CR6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1535-7163.MCT-09-0367","volume":"8","author":"JJ Short","year":"2009","unstructured":"Short JJ, Curiel DT . Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther 2009; 8: 2096\u201302.","journal-title":"Mol Cancer Ther"},{"key":"BFaps2017100_CR7","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/sj.gt.3302346","volume":"11","author":"AA Rivera","year":"2004","unstructured":"Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004; 11: 1694\u2013702.","journal-title":"Gene Ther"},{"key":"BFaps2017100_CR8","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/v2102196","volume":"2","author":"T Ranki","year":"2010","unstructured":"Ranki T, Hemminki A . Serotype chimeric human adenoviruses for cancer gene therapy. Viruses 2010; 2: 2196\u2013212.","journal-title":"Viruses"},{"key":"BFaps2017100_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1172\/JCI9973","volume":"105","author":"T Hermiston","year":"2000","unstructured":"Hermiston T . Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169\u201372.","journal-title":"J Clin Invest"},{"key":"BFaps2017100_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ymthe.2004.12.003","volume":"11","author":"XY Liu","year":"2005","unstructured":"Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531\u201341.","journal-title":"Mol Ther"},{"key":"BFaps2017100_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/hum.2010.058","volume":"22","author":"X He","year":"2011","unstructured":"He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, et al. 5\/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther 2011; 22: 283\u201392.","journal-title":"Hum Gene Ther"},{"key":"BFaps2017100_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cgt.2009.57","volume":"17","author":"C Yang","year":"2010","unstructured":"Yang C, Tong Y, Ni W, Liu J, Xu W, Li L, et al. Inhibition of autophagy induced by overexpression of mda-7\/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther 2010; 17: 109\u201319.","journal-title":"Cancer Gene Ther"},{"key":"BFaps2017100_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.drup.2005.11.001","volume":"8","author":"T Mashima","year":"2005","unstructured":"Mashima T, Tsuruo T . Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat 2005; 8: 339\u201343.","journal-title":"Drug Resist Updat"},{"key":"BFaps2017100_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4161\/cbt.11.2.14622","volume":"11","author":"N Chen","year":"2011","unstructured":"Chen N, Karantza V . Autophagy as a therapeutic target in cancer. Cancer Biol Ther 2011; 11: 157\u201368.","journal-title":"Cancer Biol Ther"},{"key":"BFaps2017100_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.cdd.4402233","volume":"15","author":"Y Chen","year":"2008","unstructured":"Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB . Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008; 15: 171\u201382.","journal-title":"Cell Death Differ"},{"key":"BFaps2017100_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.cdd.4401651","volume":"12","author":"M H\u00f8yer-Hansen","year":"2005","unstructured":"H\u00f8yer-Hansen M, Bastholm L, Mathiasen IS, Elling F, J\u00e4\u00e4ttel\u00e4 M . Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ 2005; 12: 1297\u2013309.","journal-title":"Cell Death Differ"},{"key":"BFaps2017100_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.leukres.2006.06.021","volume":"31","author":"W Qian","year":"2007","unstructured":"Qian W, Liu J, Jin J, Ni W, Xu W . Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 2007; 31: 329\u201339.","journal-title":"Leuk Res"},{"key":"BFaps2017100_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood-2006-10-050260","volume":"110","author":"JS Carew","year":"2007","unstructured":"Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110: 313\u201322.","journal-title":"Blood"},{"key":"BFaps2017100_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18632\/oncotarget.1018","volume":"4","author":"Y Tong","year":"2013","unstructured":"Tong Y, You L, Liu H, Li L, Meng H, Qian Q, et al. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget 2013; 4: 860\u201374.","journal-title":"Oncotarget"},{"key":"BFaps2017100_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K . Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 2014; 19: 3\u20139.","journal-title":"Int J Clin Oncol"},{"key":"BFaps2017100_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u201361.","journal-title":"Leukemia"},{"key":"BFaps2017100_CR22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070\u20139.","journal-title":"Blood"},{"key":"BFaps2017100_CR23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/cdd.2009.46","volume":"16","author":"E Laane","year":"2009","unstructured":"Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Oscarsson J, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009; 16: 1018\u201329.","journal-title":"Cell Death Differ"},{"key":"BFaps2017100_CR24","doi-asserted-by":"publisher","first-page":"29989","DOI":"10.1074\/jbc.M109.090530","volume":"285","author":"DJ Goussetis","year":"2010","unstructured":"Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC . Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010; 285: 29989\u201397.","journal-title":"J Biol Chem"},{"key":"BFaps2017100_CR25","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1038\/cddis.2010.53","volume":"1","author":"N Heidari","year":"2010","unstructured":"Heidari N, Hicks MA, Harada H . GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010; 1: e76.","journal-title":"Cell Death Dis"},{"key":"BFaps2017100_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI39987","volume":"120","author":"L Bonapace","year":"2010","unstructured":"Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010; 120: 1310\u201323.","journal-title":"J Clin Invest"},{"key":"BFaps2017100_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1089\/10430340252809784","volume":"13","author":"FA Kruyt","year":"2002","unstructured":"Kruyt FA, Curiel DT . Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485\u201395.","journal-title":"Hum Gene Ther"},{"key":"BFaps2017100_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/104303403766682205","volume":"14","author":"DE Post","year":"2003","unstructured":"Post DE, Khuri FR, Simons JW, Van Meir EG . Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933\u201346.","journal-title":"Hum Gene Ther"},{"key":"BFaps2017100_CR29","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1210\/en.2007-0752","volume":"148","author":"S Libertini","year":"2007","unstructured":"Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroidcarcinoma cells. Endocrinology 2007; 148: 5186\u201394.","journal-title":"Endocrinology"},{"key":"BFaps2017100_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/aps.2009.147","volume":"11","author":"HT Meng","year":"2009","unstructured":"Meng HT, Li L, Liu H, Wang Y, Li GC, Qian W . Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in the treatment of leukemia. Acta Pharmacol Sin 2009; 11: 1529\u201336.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2017100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2017100","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/aps.2017.100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/aps2017100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:35:10Z","timestamp":1684413310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2017100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFaps2017100"],"URL":"https:\/\/doi.org\/10.1038\/aps.2017.100","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"7 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}